GLP-1 & Metabolic Health News Editorial Team

GLP-1 Drugs Tame Brain's Craving Circuits for Alcohol

Clinical trials indicate semaglutide significantly reduces heavy drinking days by dampening brain reward signals. This article details the mechanism and latest study findings.

FDA Approves Mounjaro for Heart Risk in Type 2 Diabetes

The FDA approved Mounjaro to lower heart attack and stroke risk in diabetic patients. We analyze the SURPASS-CVOT data, regulatory significance, and what this means for metabolic health management.

Sleep Apnea Endotypes: Which Patients Respond Best to Zepbound?

New 2026 research reveals that Zepbound produces dramatic AHI reductions in a specific 'strong response' sleep apnea endotype. Learn who qualifies for these remission-level outcomes.

Lilly Launches Retatrutide Expanded Access Program in August 2026

Eli Lilly officially launches a compassionate use program for experimental triple-hormone drug retatrutide. We break down the rigorous BMI requirements, physician application process, and real-world implications for patients who cannot enroll in clinical trials.

Bone Health and GLP-1s: New Data Clears Up 2026 Confusion

Early 2026 warnings about GLP-1 induced osteoporosis clash with new August 2026 research showing a 21% drop in fracture risk for Type 2 diabetics.

BMJ Study Links GLP-1 Drugs to Higher Hair Loss Risk

Major new study links popular weight loss drugs to increased alopecia risk. Analysis of 550,000 patients shows higher rates of hair loss compared to other diabetes meds.

Shifting GLP-1 Delivery: Oral Approvals and Monthly Dosing in 2026

Explore how 2026 marks a pivotal shift in GLP-1 administration, featuring the first FDA-approved oral non-peptide option, monthly injectable pipelines, and new clinical perspectives on metabolic health.

Lilly's Retatrutide Hits 30% Weight Loss Threshold in Phase 3

Eli Lilly Reports Breakthrough Data from TRIUMPH-1 Obesity Trial Eli Lilly has released top-line results from the pivotal Phase 3 TRIUMPH-1 trial for retatrutid...

Kidney Benefits of Semaglutide Solidify With 2026 Data

A Paradigm Shift in Renal Care While the metabolic advantages of glucagon-like peptide-1 (GLP-1) receptor agonists initially dominated clinical discourse, devel...

Medicare GLP-1 Bridge Launches July 2026: Coverage and Eligibility

On Monday, July 1, 2026, the path to metabolic health care for older Americans shifted dramatically. After years of legislative debate and funding uncertainties...

Untitled

Untitled